Dataset Information

Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants.

ABSTRACT:

Background

Conflicting data suggest that statins could cause chronic liver disease in certain group of patients, while improving prognosis in those with chronic viral hepatitis (CVH).

Purpose

To quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on CVH patients.Data Sources: The search strategy was explored by a medical librarian using bibliographic databases, from January 2015 to April 2020.Data synthesis: The results showed no significant difference in the risk of mortality between statin users and non-users in the overall analysis. However, the risk of mortality significantly reduced by 39% in statin users who were followed for more than three years. Moreover, the risk of HCC, fibrosis, and cirrhosis in those on statins decreased by 53%, 45% and 41%, respectively. Although ALT and AST reduced slightly following statin therapy, this reduction was not statistically significant.

Limitations

A significant heterogeneity among studies was observed, resulting from differences in clinical characteristics between statin users and non-users, study designs, population samples, diseases stage, comorbidities, and confounding covariates.

Conclusion

Not only long-term treatment with statins seems to be safe in patients affected by hepatitis, but also it significantly improves their prognosis.

SUBMITTER: Vahedian-Azimi A

PROVIDER: S-EPMC8317925 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants.

Vahedian-Azimi Amir A Shojaie Sajad S Banach Maciej M Heidari Farshad F Cicero Arrigo F G AFG Khoshfetrat Masoum M Jamialahmadi Tannaz T Sahebkar Amirhossein A

Annals of medicine 20211201 1

<h4>Background</h4>Conflicting data suggest that statins could cause chronic liver disease in certain group of patients, while improving prognosis in those with chronic viral hepatitis (CVH).<h4>Purpose</h4>To quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on CVH patients.<b>Data Sources:</b> The search strategy was explored by a medical librarian using bibliographic databases, from January 2015 to April 2020.<b>Data synthesis:</b ...[more]

PMID: 34296976

Similar Datasets

Project description:BackgroundRecent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population.MethodsUsing the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis.ResultsWhen comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05).ConclusionsElevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation.

Dataset Information

Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants.

Background

Purpose

Limitations

Conclusion

Publications

Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets